LIPT - Liraglutide in Polycystic Ovary Syndrome
NCT02073929 on ClinicalTrials.gov · last registry update 2019-02-28
Finished December 2015, after enrolling 72 people. Primary outcome, as filed: Change in Endogenous Thrombin Potential (ETP). liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Jens Faber
- Sponsor type
- Other
- Enrollment
- 72
- Started
- 2014-03
- Primary completion
- 2015-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Endogenous Thrombin Potential (ETP)
Conditions studied
Polycystic Ovary Syndrome · Cardiovascular Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.